Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar Monotherapy in Drug-Naïve Type 2 Diabetes
NCT01691755Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Aleglitazar with Placebo (2 arms). Primary endpoint: Change from baseline in hemoglobin HbA1c at 26 weeks. Started Nov 2012; status: completed.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01691755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01691755.